These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28749177)

  • 21. Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results.
    Huang C; Dhruva SS; Coppi AC; Warner F; Li SX; Lin H; Nasir K; Krumholz HM
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29133522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Estimated Pulse Wave Velocity With Survival: A Secondary Analysis of SPRINT.
    Vlachopoulos C; Terentes-Printzios D; Laurent S; Nilsson PM; Protogerou AD; Aznaouridis K; Xaplanteris P; Koutagiar I; Tomiyama H; Yamashina A; Sfikakis PP; Tousoulis D
    JAMA Netw Open; 2019 Oct; 2(10):e1912831. PubMed ID: 31596491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
    Mancia G; Kjeldsen SE; Zappe DH; Holzhauer B; Hua TA; Zanchetti A; Julius S; Weber MA
    Eur Heart J; 2016 Mar; 37(12):955-64. PubMed ID: 26590384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
    Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
    Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
    Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
    Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
    Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial).
    Shapiro BP; Ambrosius WT; Blackshear JL; Cushman WC; Whelton PK; Oparil S; Beddhu S; Dwyer JP; Gren LH; Kostis WJ; Lioudis M; Pisoni R; Rosendorff C; Haley WE;
    Hypertension; 2018 Jun; 71(6):1064-1074. PubMed ID: 29712745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Diastolic Blood Pressure is Not Related to Risk of First Episode of Stroke in a High-Risk Population: A Secondary Analysis of SPRINT.
    Sobieraj P; Lewandowski J; Siński M; Symonides B; Gaciong Z
    J Am Heart Assoc; 2019 Feb; 8(4):e010811. PubMed ID: 30744452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis.
    Verdecchia P; Angeli F; Gentile G; Reboldi G
    Hypertension; 2016 Sep; 68(3):642-53. PubMed ID: 27456518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Risk in Hypertension in Relation to Achieved Blood Pressure Using Automated Office Blood Pressure Measurement.
    Myers MG; Kaczorowski J; Dolovich L; Tu K; Paterson JM
    Hypertension; 2016 Oct; 68(4):866-72. PubMed ID: 27528062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visit-to-visit systolic blood pressure variability predicts treatment-related adverse event of hyponatremia in SPRINT.
    Goyal A; Mezue K; Rangaswami J
    Cardiovasc Ther; 2017 Aug; 35(4):. PubMed ID: 28544636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial.
    Oxlund CS; Pareek M; Rasmussen BSB; Vaduganathan M; Biering-Sørensen T; Byrne C; Almarzooq Z; Olsen MH; Bhatt DL
    Am J Med; 2019 Jul; 132(7):840-846. PubMed ID: 30721655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [120 mmHg for everyone?].
    Wiersma T
    Ned Tijdschr Geneeskd; 2016; 160():A9894. PubMed ID: 27071362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients.
    Kario K; Iwashita M; Okuda Y; Sugiyama M; Saito I; Kushiro T; Teramukai S; Shimada K
    Hypertension; 2018 Oct; 72(4):854-861. PubMed ID: 30354719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system.
    Elliott HL; Lloyd SM; Ford I; Meredith PA
    Blood Press; 2016; 25(2):67-73. PubMed ID: 26796694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [SPRINT study: far lower systolic blood pressure].
    Souček M; Řiháček I; Novák J
    Cas Lek Cesk; 2016; 155(4):9-12. PubMed ID: 27481195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.